Brain apoE4 is hypolipidated relative to apoE3 [7, 25] and we have recently shown that treatment with the ABCA1 agonist CS-6253 reverses the hypolipidation of apoE4 and concomitantly counteracts the apoE4-driven brain pathology and cognitive impairments [25]. Here, ABCA1 is linked to Cognitive impairment.